利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

205 条记录 (耗时 0.025 秒)

    AAV ISOLATE AND FUSION PROTEIN COMPRISING NERVE GROWTH FACTOR SIGNAL PEPTIDE AND PARATHYROID HORMONE
    3.
    发明公开
    AAV ISOLATE AND FUSION PROTEIN COMPRISING NERVE GROWTH FACTOR SIGNAL PEPTIDE AND PARATHYROID HORMONE 审中-公开

    公开(公告)号：EP3294894A1

    公开(公告)日：2018-03-21

    申请号：EP16727258

    申请日：2016-05-12

    申请人： THE U S A AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES

    发明人： CHIORINI JOHN A ,  DI PASQUALE GIOVANNI

    IPC分类号： C12N15/86 ,  C07K14/635

    CPC分类号： C12N15/86 ,  C07K14/635 ,  C07K2319/02 ,  C12N9/90 ,  C12N2750/14122 ,  C12N2750/14143

    摘要： The invention provides an adeno-associated viral (AAV) vector comprising a capsid comprising the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 9, wherein the AAV vector further comprises a heterologous nucleic acid sequence, and wherein the heterologous nucleic acid sequence can encode the NGF-PTH fusion polypeptide or methylmalonyl CoA mutase enzyme. The invention also provides a polypeptide comprising nerve growth factor (NGF) signal peptide and parathyroid hormone (PTH), wherein the polypeptide can comprise, consist essentially of, or consist of the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2. The invention provides a nucleic acid encoding the polypeptide, a vector comprising the nucleic acid, and a composition comprising the polypeptide, nucleic acid, or vector, as well as treatment methods comprising the polypeptide, nucleic acid, vector, or composition. The invention further provides a method of treating methylmalonic acidaemia (MMA) in a mammal comprising administering an AAV vector comprising a heterologous nucleic acid sequence encoding methylmalonyl CoA mutase enzyme to the mammal.

    Supplemented matrices for the repair of bone fractures
    6.
    发明公开
    Supplemented matrices for the repair of bone fractures 审中-公开
    补充矩阵为骨折的修复

    公开(公告)号：EP2316497A3

    公开(公告)日：2014-05-07

    申请号：EP10181752.6

    申请日：2006-01-06

    申请人： Kuros Biosurgery AG

    发明人： Schense, Jason ,  Watson, John ,  Arrighi, Isabelle

    IPC分类号： A61L27/22 ,  A61L27/12 ,  A61L27/46 ,  A61K38/29 ,  C07K14/635

    CPC分类号： A61K38/29 ,  A61L27/12 ,  A61L27/225 ,  A61L27/227 ,  A61L27/46 ,  A61L2430/02 ,  C07K14/635 ,  C07K2319/00

    摘要： Supplemented matrices comprising a PTH releasably incorporated therein, optionally containing a granular material, are described herein. The PTH is incorporated either through covalent linkage to the matrix or through non-covalent interaction with the matrix and/or the granules. These supplemented matrices decrease the time of healing compared to autograft and or trigger healing of bone fractures which otherwise would not heal. The matrices are biocompatible and biodegradable and can be formed in vitro or in vivo , at the time of implantation. The PTH may be a part of a fusion peptide. PTH can be incorporated into the matrices with full retention of its bioactivity. PTH can be releasably incorporated, using techniques that provide control over how and when and to what degree the PTH is released using the matrix as a controlled release vehicle to heal bone fractures.

    SHORT-CHAIN PEPTIDES AS PARATHYROID HORMONE (PTH) RECEPTOR AGONIST
    9.
    发明公开
    SHORT-CHAIN PEPTIDES AS PARATHYROID HORMONE (PTH) RECEPTOR AGONIST 审中-公开
    抗坏血酸肽（PTH）-REZEPTORAGONIST

    公开(公告)号：EP2421893A2

    公开(公告)日：2012-02-29

    申请号：EP10747683.0

    申请日：2010-04-26

    申请人： Cadila Healthcare Limited

    发明人： BAHEKAR, Rajesh ,  JAIN, Mukul R. ,  PATEL, Pankaj R.

    IPC分类号： C07K14/635

    CPC分类号： C07K14/635 ,  A61K38/00

    摘要： The present invention provides novel short-chain peptides, which primarily act as parathyroid hormone (PTH/ PTH-I) receptor agonist. These short-chain peptides exhibit increased stability to proteolytic cleavage. Most of short-chain peptides were found to be stable in rat plasma upto 24 hours (
    in vitro ), showed increased stability against GIT enzymes such as pepsin and acidic stomach pH and also against liver microsomes (
    in vitro ). Due to increased metabolic stability, other than parenteral route of administration, some of the short-chain peptides can also be delivered by oral routes of administration, for the treatment / prevention of hypoparathyroidism and diseases characterized by bone mass reduction, such as osteoporosis, postmenopausal osteoporosis and for stimulating bone repair. A-Z
    1 -Z
    2 -Z
    3 -Z
    4 -Z
    5 -Z
    6 -Z
    7 -Z
    8 -Z
    9 -Z
    10 -Z
    11 -Z
    12 -Z
    13 -Z
    14 -Z
    15 -B

    摘要翻译： 本发明提供了主要作为甲状旁腺激素（PTH / PTH-1）受体激动剂的新型短链肽。 这些短链肽表现出增加的蛋白水解切割的稳定性。 发现大多数短链肽在大鼠血浆中稳定至多24小时（体外），显示出对GIT酶如胃蛋白酶和酸性胃pH以及针对肝微粒体（体外）的稳定性增加。 由于增加的代谢稳定性，除了肠胃外给药途径之外，一些短链肽也可以通过口服给药途径递送，用于治疗/预防甲状旁腺功能减退症和以骨量减少为特征的疾病，如骨质疏松症，绝经后 骨质疏松症和刺激骨修复。 A-Z1-Z2-Z3-Z4-Z5-Z6-Z7-Z8-Z9-Z10-Z11-Z12-Z13-Z14-Z15-B